Aktienanalyse zu Soligenix Inc (SNGX)SNGXSoligenix Inc

Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Soligenix Inc is not a good buy right now due to its current price of $0.34, which is significantly below its 52-week high of $1.70, indicating a 76.40% year-to-date decline. Additionally, the RSI is at 30.79, suggesting that the stock is oversold but could continue to decline. The forward P/E ratio of 12.32 indicates potential future profitability, but the company has consistently reported negative earnings, with the latest EPS at -0.05, which raises concerns about its financial health.

3 analysts cover SNGX: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 10.00.